Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sturlimogene Erparepvec

Plasma-derived product · Kills target cells · developed by Replimune

Phase 2/3 Most advanced trial
REPL Developer
4 Registered trials

What is Sturlimogene Erparepvec?

Sturlimogene erparepvec is a genetically modified herpes simplex virus type 1 that replicates in and lyses tumor cells. It expresses GM-CSF and an antibody-like molecule against CTLA-4, which together promote a cytotoxic T-lymphocyte response against tumor cells. It is studied in hepatocellular carcinoma, biliary tract cancer, uveal melanoma, cutaneous melanoma and high-risk oral precancerous disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RP2, RP2 Monotherapy
Drug type
Plasma-derived product
Mechanism
Kills target cells
Pathways
T-cell activation, dendritic cell recruitment, cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Replimune, Inc. (REPL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
53Z5E7R5KD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06581406 Phase 2/3 Metastatic Uveal Melanoma Recruiting REPL
NCT07862530 Phase 2 MelanomaCutaneous Melanoma Resectable, Melanoma Not yet recruiting REPL
NCT06623110 Phase 2 High-Risk Oral Precancerous Disease Recruiting REPL
NCT05733598 Phase 2 Hepatocellular Carcinoma Recruiting REPL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract CancerHepatocellular CarcinomaHigh-Risk Oral Precancerous DiseaseMelanomaCutaneous Melanoma Resectable, MelanomaMetastatic Uveal Melanoma

More from Replimune

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.

Follow REPL, the company behind Sturlimogene Erparepvec

See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REPL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.